Telix Pharmaceuticals Limited is convening a general meeting on December 1, 2026, to seek shareholder approval for its proposed acquisition of 100% of ITM Isotope Technologies Munich SE. The transaction involves an upfront consideration valued at US$1.65 billion and contingent milestone payments of up to US$700 million based on regulatory approvals and commercial sales of ITM-11. Telix will issue shares as part of the consideration, requiring approval for maximum upfront, regulatory, and future sales milestone share issuances under ASX Listing Rule 7.1. The Board also seeks approval to elect Dr. Andrew Cavey and Dr. Barbara Weber as new directors effective upon closing. Telix Pharmaceuticals Limited is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer treatment.
